chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

March 12, 2020March 12, 2020

CLR 131 Shows Anti-tumor Activity, Safety in Difficult-to-treat B-cell Lymphoma Trial

News

Cellectar Biosciences has announced positive trial results demonstrating that its investigational therapy CLR 131 significantly reduced tumor activity, with tolerable safety, in B-cell lymphoma patients who received prior treatments. A “notable” ... Read more

January 30, 2020January 30, 2020

Imbruvica Plus Rituximab Prolongs Survival in Untreated CLL/SLL Patients, Phase 3 Trial Finds

News

Imbruvica (ibrutinib) in combination with rituximab continues to prolong survival and the time without disease progression in previously untreated adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ... Read more

August 27, 2019

Cirmtuzumab-Imbruvica Combo Trial Enrolling CLL, SLL Patients for Phase 2

News

Following promising early efficacy results for a cirmtuzumab–Imbruvica treatment combo, a Phase 2 clinical trial has now been opened to people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The opening of ... Read more